Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Spatz

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)Antonia Busse, Jérôme Rapion, Alberto Fusi, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2011
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
Cancers|November 13, 2025
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate CancerSoumaya Labidi, Belinda Jiao, Shirley Tam, et al.
Proteomics. Clinical Applications|July 10, 2020
Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer CellsBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
Cancer Treatment and Research Communications|November 13, 2021
Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomasNicole Ezer, Hangjun Wang, Andrea Gomez Corredor, et al.
The Analyst|September 29, 2021
A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissuesBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
Cancers|December 7, 2019
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic DataBernhard Blank-Landeshammer, Vincent R Richard, Georgia Mitsa, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)Antonia Busse, Jérôme Rapion, Alberto Fusi, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2011
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
Cancers|November 13, 2025
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate CancerSoumaya Labidi, Belinda Jiao, Shirley Tam, et al.
Proteomics. Clinical Applications|July 10, 2020
Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer CellsBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
Cancer Treatment and Research Communications|November 13, 2021
Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomasNicole Ezer, Hangjun Wang, Andrea Gomez Corredor, et al.
The Analyst|September 29, 2021
A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissuesBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
Cancers|December 7, 2019
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic DataBernhard Blank-Landeshammer, Vincent R Richard, Georgia Mitsa, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
Pageof 8